First-Line Alectinib vs. Brigatinib in Advanced Non–Small Cell Lung Cancer with ALK Rearrangement: Real-World Data
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Alectinib and brigatinib are second-generation anaplastic lymphoma receptor tyrosine kinases (ALKs) that are widely used as first-line therapy for treating ALK-positive advanced non–small cell lung cancer (NSCLC). Given the lack of a head-to-head comparison of these drugs as first-line therapies, this retrospective observational study aimed to compare the real-world efficacy and safety of alectinib and brigatinib. Materials and Methods Patients who received alectinib or brigatinib as the first-line treatment for ALK-positive advanced NSCLC were evaluated for clinical outcomes of objective response rate (ORR), intracranial ORR, time to next treatment (TTNT), progression-free survival (PFS), overall survival (OS), and safety profiles. Results Of 208 patients who received either alectinib or brigatinib as a first-line treatment, 176 received alectinib and 32 received brigatinib. At the data cutoff point, the median follow-up duration was 16.5 months (95% confidence interval [CI], 14.7 to 18.3) in the brigatinib group and 27.5 months (95% CI, 24.6 to 30.4) in the alectinib group. The ORR was 92.5% with alectinib and 93.8% for brigatinib. The intracranial ORR rates were 92.7% (38/41) and 100% (10/10), respectively. The rate of PFS at 12 months was comparable between the alectinib group and the brigatinib groups (84.4% vs. 84.1%, p=0.64), and the median TTNT, PFS, and OS were not reached in either group. Treatment-related adverse events were usually mild, and treatment discontinuation due to adverse events was rare (alectinib 4.5% vs. brigatinib 6.25%). Conclusion Alectinib and brigatinib had similar clinical benefits when used as the first-line treatment of NSCLC patients with ALK rearrangement in the real world.
Abstract
Purpose Alectinib and brigatinib are second-generation anaplastic lymphoma receptor tyrosine kinases (ALKs) that are widely used as first-line therapy for treating ALK-positive advanced non–small cell lung cancer (NSCLC). Given the lack of a head-to-head comparison of these drugs as first-line therapies, this retrospective observational study aimed to compare the real-world efficacy and safety of alectinib and brigatinib. Materials and Methods Patients who received alectinib or brigatinib as the first-line treatment for ALK-positive advanced NSCLC were evaluated for clinical outcomes of objective response rate (ORR), intracranial ORR, time to next treatment (TTNT), progression-free survival (PFS), overall survival (OS), and safety profiles. Results Of 208 patients who received either alectinib or brigatinib as a first-line treatment, 176 received alectinib and 32 received brigatinib. At the data cutoff point, the median follow-up duration was 16.5 months (95% confidence interval [CI], 14.7 to 18.3) in the brigatinib group and 27.5 months (95% CI, 24.6 to 30.4) in the alectinib group. The ORR was 92.5% with alectinib and 93.8% for brigatinib. The intracranial ORR rates were 92.7% (38/41) and 100% (10/10), respectively. The rate of PFS at 12 months was comparable between the alectinib group and the brigatinib groups (84.4% vs. 84.1%, p=0.64), and the median TTNT, PFS, and OS were not reached in either group. Treatment-related adverse events were usually mild, and treatment discontinuation due to adverse events was rare (alectinib 4.5% vs. brigatinib 6.25%). Conclusion Alectinib and brigatinib had similar clinical benefits when used as the first-line treatment of NSCLC patients with ALK rearrangement in the real world.
참고문헌 (24)
- "Global cancer observatory: cancer today" (2020)[URL]
- Duma N, "Non-small cell lung cancer : epidemiology, screening, diagnosis, and treatment", Mayo Clin Proc, 94, pp.1623~1640 (2019)
- Kalemkerian GP, "Molecular testing guideline for the selection of patients with lung cancer for treatment with tar geted tyrosine kinase inhibitors : American Society of Clinical Oncology Endorsement of the College of American Patholo gists", International Association for the Study of Lung Cancer, J Clin Oncol, pp.2018, 36[DOI]
- Kwak EL, "Anaplastic lymphoma kinase inhibition in non small-cell lung cancer", N Engl J Med, 363, pp.1693~1703 (2010)
- Gambacorti-Passerini C, "Crizotinib in anaplastic large-cell lymphoma", N Engl J Med, 364, pp.775~776 (2011)
- Morris TA, "Targeting ROS1 rearrange ments in non-small cell lung cancer : crizotinib and newer generation tyrosine kinase inhibitors", Drugs, 79, pp.1277~1286 (2019)
- Rotow J, "Understanding and targeting resistance mechanisms in NSCLC", Nat Rev Cancer, 17, pp.637~658 (2017)
- Griesinger F, "Brain metastases in ALK-positive NSCLC : time to adjust current treatment algorithms", Oncotarget, 9, pp.3518194~ (2018)
- Johung KL, "Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis", J Clin Oncol, 34, pp.123~129 (2016)
- Gainor JF, "The central nervous system as a sanctuary site in ALK-positive non small-cell lung cancer", J Thorac Oncol, 8, pp.1570~1573 (2013)
- Sullivan I, "ALK inhibitors in non-small cell lung cancer : the latest evidence and developments", Ther Adv Med Oncol, 8, pp.32~47 (2016)
- Zhang S, "The potent ALK inhibitor brigatinib(AP26113)over comes mechanisms of resistance to first-and second-gener ation ALK inhibitors in preclinical models", Clin Cancer Res, 22, pp.5527~5538 (2016)
- Seto T, "CH5424802(RO5424802)for patients with ALK-rearranged advanced non-small-cell lung cancer(AF 001JP study) : a single-arm, open-label, phase 1-2 study", Lancet Oncol, 14, pp.590~598 (2013)
- Peters S, "Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer", N Engl J Med, 377, pp.829~838 (2017)
- Camidge DR, "Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study", J Thorac Oncol, 14, pp.1233~1243 (2019)
- Camidge DR, "Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer", N Engl J Med, 379, pp.2027~2039 (2018)
- Camidge DR, "Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC : final results of phase 3 AL TA-1L trial", J Thorac Oncol, 16, pp.2091~2108 (2021)
- Carcereny E, "Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first line treatment for ALK+ NSCLC using an in silico systems biology-based approach", Oncotarget, 12, pp.316~332 (2021)
- Ando K, "Brigatinib and alectinib for ALK rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis : a systematic review and network meta-analysis", Cancers(Basel), 12, pp.942~ (2020)
- Reckamp KL, "Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer", Future Oncol, 18, pp.2499~2510 (2022)
- Yu Y, "Comparison of efficacy and safety of brigatinib in first-line treatments for patients with anaplas tic lymphoma kinase-positive non-small-cell lung cancer : a systematic review and indirect treatment comparison", J Clin Med, 11, pp.2963~ (2022)
- Nishio M, "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-pos itive non-small-cell lung cancer", Lung Cancer, 121, pp.37~40 (2018)
- Popat S, "Brigatinib vs. alectinib in crizotinib-resistant advanced anaplastic lym phoma kinase-positive non-small-cell lung cancer(ALTA-3)", Future Oncol, 17, pp.4237~4247 (2021)
- Hida T, "Alectinib versus crizotinib in patients with ALK-posi tive non-small-cell lung cancer(J-ALEX) : an open-label, ran domised phase 3 trial", Lancet, 390, pp.29~39 (2017)